Marrone Bio Innovations Inc (NASDAQ:MBII) shares shot up 0.7% during mid-day trading on Monday . The company traded as high as $1.41 and last traded at $1.39, 681 shares changed hands during trading. A decline of 100% from the average session volume of 206,107 shares. The stock had previously closed at $1.38.
A number of research firms recently issued reports on MBII. Aegis began coverage on Marrone Bio Innovations in a report on Wednesday, July 24th. They set a “buy” rating and a $2.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $2.50 price objective on shares of Marrone Bio Innovations in a report on Monday, August 12th. Finally, National Securities restated a “buy” rating and set a $2.50 price objective on shares of Marrone Bio Innovations in a report on Friday, August 9th.
The stock has a fifty day moving average of $1.42 and a 200-day moving average of $1.50. The company has a debt-to-equity ratio of 6.69, a quick ratio of 1.04 and a current ratio of 1.53. The company has a market cap of $152.81 million and a PE ratio of -6.71.
Marrone Bio Innovations (NASDAQ:MBII) last posted its quarterly earnings data on Thursday, August 8th. The basic materials company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.02). Marrone Bio Innovations had a negative net margin of 86.09% and a negative return on equity of 193.23%. The business had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $9.01 million. As a group, equities analysts anticipate that Marrone Bio Innovations Inc will post -0.2 EPS for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new position in Marrone Bio Innovations during the 1st quarter valued at $74,000. BlackRock Inc. lifted its holdings in shares of Marrone Bio Innovations by 0.8% in the 2nd quarter. BlackRock Inc. now owns 2,657,546 shares of the basic materials company’s stock worth $3,986,000 after buying an additional 22,254 shares during the period. River & Mercantile Asset Management LLP purchased a new stake in shares of Marrone Bio Innovations in the 2nd quarter worth $843,000. Susquehanna International Group LLP purchased a new stake in shares of Marrone Bio Innovations in the 2nd quarter worth $30,000. Finally, A.R.T. Advisors LLC purchased a new stake in shares of Marrone Bio Innovations in the 2nd quarter worth $28,000. Institutional investors own 42.99% of the company’s stock.
Marrone Bio Innovations Company Profile (NASDAQ:MBII)
Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.
Featured Story: Is the QQQ ETF safe?
Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.